Dr. Mamounas on Selecting Patients With Breast Cancer for Neoadjuvant Chemotherapy

Eleftherios P. Mamounas, MD
Published: Thursday, Oct 23, 2014

Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.

There are breast cancer subtypes that respond very well to neoadjuvant chemotherapy: triple-negative, HER2-positive, and ER-positive. Once a pathologic complete response is achieved, the oncologist should be aware of clinical trials that test the concept of less aggressive treatment.

It is important to select patients for neoadjuvant chemotherapy, not only by size or nodal status, but also by subtype.
 
Eleftherios Mamounas, MD, MPH, medical director, Comprehensive Breast Program, University of Florida Health Cancer Center, discusses the need to select patients for neoadjuvant chemotherapy.

There are breast cancer subtypes that respond very well to neoadjuvant chemotherapy: triple-negative, HER2-positive, and ER-positive. Once a pathologic complete response is achieved, the oncologist should be aware of clinical trials that test the concept of less aggressive treatment.

It is important to select patients for neoadjuvant chemotherapy, not only by size or nodal status, but also by subtype.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x